Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer (NCT06958328)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. At time of enrollment, the patient must have received 4-8 months of active chemotherapy with FOLFIRINOX or NALIRIFOX or gemcitabine/nab-paclitaxel. Patients are permitted to receive more than 1 type of chemotherapy for reasons other than radiographic progression by Response Evaluation Criteria in Solid Tumors (RECIST) (i.e. chemotherapy regimen switch is allowed for toxicity, and/or switch is allowed for toxicity and/or CA19-9 level not declining). Patients are allowed to receive chemotherapy after restaging scans, as long as 1) restaging scans are performed after at least 4 months of chemotherapy and 2) the total chemotherapy duration does not exceed 8 months
2. "Active chemotherapy" refers to time on chemotherapy not counting treatment breaks (i.e. if a patient had 1 month of chemotherapy followed by 1 month break, this would count as 1 month chemotherapy). Study registration must occur within 45 days of last day of pre-study entry chemotherapy
3. BASELINE PRE-ENTRY CHEMOTHERAPY REQUIREMENTS:
4. Pathologically (histologically or cytologically) proven diagnosis of pancreatic ductal adenocarcinoma
5. Locally advanced unresectable disease (as defined per the National Comprehensive Cancer Network \[NCCN\] guidelines and institutional tumor board review)
6. Patients must have baseline pre-chemotherapy scans for staging. Options include: CT chest/abdomen/pelvis, CT chest/MRI abdomen/pelvis, CT chest/CT pelvis/MRI abdomen, or PET/CT performed prior to enrollment
7. Age ≥ 18 years
8. Performance status Eastern Cooperative Oncology Group (ECOG) 0-2
9. Required initial laboratory values: All laboratory values must be obtained any time prior to initiation of chemotherapy up to 30 days post initiation of chemotherapy
10. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN)
11. BASELINE CA19-9 AND BILIRUBIN REQUIREMENTS: The purpose is to obtain a baseline CA19-9 in the setting of a normal (or close to normal) bilirubin, since serologic response by serial CA19-9 measurements is part of post-chemotherapy eligibility criteria
12. If baseline CA19-9 \> 37 U/mL the concurrent bilirubin must be ≤ 1.5 x ULN. (Note: if the bilirubin is not ≤ 1.5 x ULN both the CA19-9 and concurrent bilirubin can be repeated until bilirubin is ≤ 1.5 x ULN, as long as done within specified timeframe \[up to 30 days post chemotherapy initiation\])

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (333 Sites)

• Banner MD Anderson Cancer Center — Gilbert, Arizona
• Arizona Center for Cancer Care - Gilbert — Gilbert, Arizona
• Arizona Center for Cancer Care-Peoria — Peoria, Arizona
• Banner-University Medical Center Phoenix — Phoenix, Arizona
• Arizona Center for Cancer Care - Phoenix — Phoenix, Arizona
• Arizona Center for Cancer Care - Scottsdale — Scottsdale, Arizona
• Arizona Center for Cancer Care-Surprise — Surprise, Arizona
• Arizona Center for Cancer Care — Tempe, Arizona
• NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
• Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
• AIS Cancer Center at San Joaquin Community Hospital — Bakersfield, California
• Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
• Mills-Peninsula Medical Center — Burlingame, California
• Sutter Cancer Centers Radiation Oncology Services-Cameron Park — Cameron Park, California
• Palo Alto Medical Foundation-Fremont — Fremont, California
• UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
• UC San Diego Moores Cancer Center — La Jolla, California
• Memorial Medical Center — Modesto, California
• Palo Alto Medical Foundation-Camino Division — Mountain View, California
• UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
• Palo Alto Medical Foundation Health Care — Palo Alto, California
• Stanford Cancer Institute Palo Alto — Palo Alto, California
• Sutter Cancer Centers Radiation Oncology Services-Roseville — Roseville, California
• Sutter Roseville Medical Center — Roseville, California
• Sutter Medical Center Sacramento — Sacramento, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.